Antheia Adds $24M in Series C Extension to Expand U.S. Biosynthetic Drug Manufacturing
Menlo Park–based Antheia has added $24 million in a second close of its Series C round, bringing its total raised over the past year to more than $175 million. The round was led by ATHOS KG and America’s Frontier Fund, with participation from Global Health Investment Corporation and EDBI, which co-led the initial Series C close.
Funds will support the commercialization of late-stage biosynthetic ingredients and domestic manufacturing aligned with U.S. government onshoring priorities. The company reports several existing government-backed projects as part of this effort and has been designated by the U.S. government as a priority technology developer for public health and national security.
Antheia is a biomanufacturing company focused on reengineering pharmaceutical supply chains through advanced biosynthesis. Spun out of Stanford University in 2015 by Dr. Christina Smolke and Dr. Kristy Hawkins, the company programs yeast to produce complex active pharmaceutical ingredients (APIs) and key starting materials (KSMs) at industrial scale.
Antheia’s platform is designed to replace vulnerable agricultural and petrochemical inputs with sustainable fermentation-based production, supporting more resilient and transparent access to essential medicines.
Recently, it completed its first commercial shipment of thebaine, an opioid precursor used to manufacture Narcan. In November 2025, Antheia entered a strategic partnership with Teva subsidiary TAPI to expand distribution of biosynthetically derived APIs.
Other leading candidates in Antheia’s pipeline include oripavine, a key starting material for multiple neurology-related APIs, and scopolamine, under development for gastrointestinal indications such as motion sickness and post-operative nausea.
To stay in the loop on how technology is reshaping biotech, including AI-driven therapeutics, biosynthesis, neural interfaces, and beyond, follow our weekly newsletter, Where Tech Meets Bio.
Topic: Biotech Ventures
